Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro (Q38989903)

8 September 2017

title

Astragaloside IV inhibits renal tubulointerstitial fibrosis by blocking TGF-β/Smad signaling pathway in vivo and in vitro (English)

1 reference

8 September 2017

Li Wang

1

1 reference

8 September 2017

Yang-Feng Chi

2

1 reference

8 September 2017

Ze-Ting Yuan

3

1 reference

8 September 2017

Wen-Chao Zhou

4

1 reference

8 September 2017

Pei-Hao Yin

5

1 reference

8 September 2017

Xue-Mei Zhang

6

1 reference

8 September 2017

Wen Peng

7

1 reference

8 September 2017

Hui Cai

8

1 reference

8 September 2017

publication date

30 May 2014

1 reference

Experimental Biology and Medicine

8 September 2017

published in

1 reference

8 September 2017

volume

239

1 reference

8 September 2017

issue

10

1 reference

8 September 2017

page(s)

1310-1324

1 reference

Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Curcumin inhibits transforming growth factor-β1-induced EMT via PPARγ pathway, not Smad pathway in renal tubular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

The role of epithelial-to-mesenchymal transition in renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Suramin inhibits renal fibrosis in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-β/Smad3-NF.κB-dependent mechanisms in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Dioscorea alata attenuates renal interstitial cellular fibrosis by regulating Smad- and epithelial-mesenchymal transition signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Asiatic acid inhibits liver fibrosis by blocking TGF-beta/Smad signaling in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Astragaloside IV improves homocysteine-induced acute phase endothelial dysfunction via antioxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Therapeutic effects of astragaloside IV on myocardial injuries: multi-target identification and network analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Astragaloside IV prevents acute kidney injury in two rodent models by inhibiting oxidative stress and apoptosis pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Astragaloside IV Attenuates Complement Membranous Attack Complex Induced Podocyte Injury Through the MAPK Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

The sialoadhesin (CD169) expressing a macrophage subset in human proliferative glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Transglutaminase inhibition ameliorates experimental diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Norcantharidin inhibits renal interstitial fibrosis by blocking the tubular epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Epithelial-mesenchymal transition in renal fibrosis - evidence for and against.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

TGF-beta signaling in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Fluorofenidone attenuates renal interstitial fibrosis in the rat model of obstructive nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Connective tissue growth factor regulates the key events in tubular epithelial to myofibroblast transition in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Smad7 as a therapeutic agent for chronic kidney diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Transforming growth factor beta1 induces nuclear export of inhibitory Smad7

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1535370214532597

21 January 2018

Identifiers

DOI

10.1177/1535370214532597

1 reference

8 September 2017

1 reference